Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is an experimental small molecule inhibitor primarily characterized as a potent and selective vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor. It belongs to the class of indazoles and pyrimidinediamines. The drug has demonstrated high binding affinity for VEGFR2 with an IC50 of approximately 6.3 nM[1]. Its mechanism involves blocking VEGFR2-mediated signaling pathways that are critical for angiogenesis—the formation of new blood vessels—which is a key process in tumor growth and metastasis. There are no approved indications or clinical trials beyond preclinical/experimental stages reported for this compound[1][7]. No developer or manufacturer information is available.
- Other names
- N4-(3-methyl-1H-indazol-6-yl)-N2-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine2,4-Pyrimidinediamine, N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)-
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine.